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Purpose: Comparing the efﬁcacy of intravitreal injections of bevacizumab to ranibizumab in the treatment of
macular edema (ME) resulting from retinal vein occlusion (RVO).
Design: Comparative, randomized, double-masked, multicenter, noninferiority clinical trial. The noninferiority
margin was 4 letters.
Participants: Patients with vision loss resulting from ME secondary to a branch or (hemi) central RVO who
might beneﬁt from antievascular endothelial growth factor treatment were eligible for participation.
Methods: From June 2012 through February 2018, 277 participants were randomized to receive injections of
1.25 mg bevacizumab (n ¼ 139) or 0.5 mg ranibizumab (n ¼ 138). The follow-up was 6 months with a monthly
dosing interval.
Main Outcome Measures: The primary outcome was a change in visual acuity from baseline at 6 months.
Changes in the central area thickness and safety were studied as secondary outcomes.
Results: The mean visual acuity (standard deviation) improved, with 15.313.0 letters for bevacizumab and
15.513.3 letters for ranibizumab after 6 months of monthly treatment. The lower limit of the 2-sided 90%
conﬁdence interval was e1.724 letters, which is within the noninferiority margin of 4 letters. Even in the branch
and (hemi-)central RVO subgroups, minimal differences were found in visual acuity outcomes between treatment
arms. Changes in central area thickness on OCT at 6 months did not differ signiﬁcantly between treatment
groups, with a decrease of 287.0231.3 mm in the bevacizumab group and 300.8224.8 mm in the ranibizumab
group. Severe adverse events (SAEs) were also distributed equally over both treatment groups: 10 participants
(7.1%) in the bevacizumab group and 13 participants (9.2%) in the ranibizumab group experienced SAEs.
Conclusions: This study showed, based on the change in visual acuity, that bevacizumab is noninferior to
ranibizumab for patientswithME resulting fromRVOof either subtypewhen receivingmonthly injections for a period
of 6 months. In addition, anatomic and safety outcomes did not differ between treatment groups. Based on our
ﬁndings, bevacizumabmay be an effective alternative to ranibizumab.Ophthalmology Retina 2020;-:1e12ª 2020
by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.the treatment of macular edema (ME) resulting from retinal
vein occlusion (RVO), but virtually no state-of-the-art
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prevalent retinal vascular disease, affecting an estimated
16 million people worldwide. Therefore, conclusive
comparisons with available anti-VEGF agents regarding
efﬁcacy, safety, and cost are needed.2e4
Three subtypes of RVO have been identiﬁed: branch
retinal vein occlusion (BRVO), central retinal vein occlu-
sion (CRVO), and hemi-central retinal vein occlusion
(hemi-CRVO), with hemi-CRVO seeming to be a variant of
CRVO, with similar pathogenesis and risk factors.5 The
development of ME is the most important cause of visual
impairment in all forms of RVO. Retinal ischemia
resulting from circulatory stasis because of venous
obstruction promotes the production of VEGF-A, leading
to increased vascular permeability and, ﬁnally, edema.5e7
Intravitreal injections for anti-VEGF therapy are the stan-
dard care for ME occurring after RVO,2,8 and the 3
commonly used anti-VEGF agents are ranibizumab, a hu-
manized high-afﬁnity antibody fragment that targets all
isoforms of VEGF-A; bevacizumab, a humanized full-
length antibody; and aﬂibercept, a complex of VEGF re-
ceptors 1 and 2 fused to a humanized monoclonal antibody
backbone.7e12 All 3 anti-VEGF agents result in signiﬁcant
improvement in visual acuity and reduced ME in patients
with BRVO and CRVO compared with sham injections or
photocoagulation, although for bevacizumab, only a few
small randomized controlled trials (RCTs) have been
reported.6,9,10,13e15 In other retinal vascular disorders,
several RCTs have compared the efﬁcacy of anti-VEGF
agents directly in patients with exudative age-related mac-
ular degeneration, demonstrating similar efﬁcacy between
bevacizumab and ranibizumab.11,12,16,17 The Diabetic
Retinopathy Clinical Research Network Protocol T study
compared all 3 anti-VEGF agents in patients with diabetic
ME and showed that at 2 years, aﬂibercept resulted in an
outcome superior to that of bevacizumab in a subgroup of
patients with lower baseline visual acuity.18,19
In patients with RVO, similar state-of-the-art compara-
tive RCTs on the efﬁcacy and safety of anti-VEGF agents
are virtually missing. However, 2 underpowered studies
comparing bevacizumab with ranibizumab have been re-
ported, the Bevacizumab versus Ranibizumab in Branch
Retinal Vein Occlusion (MARVEL) study and the Bev-
acizumab versus Ranibizumab in Treatment of Macular
Edema From Vein Occlusion (CRAVE) study, which found
a similar effect on improving visual acuity after bev-
acizumab and ranibizumab treatment in 75 BRVO patients
and 98 RVO patients, respectively.20,21 The only state-of-
the-art RCT for RVO patients with ME, the Study of
Comparative Treatments for Retinal Vein Occlusion 2
(SCORE2) study, compared bevacizumab with aﬂibercept
in 362 patients with ME resulting from CRVO or hemi-
CRVO. This study conﬁrmed the noninferiority of bev-
acizumab compared with aﬂibercept with regard to visual
outcome after 6 monthly injections.1 In the present study,
we aimed to generate similar conclusive evidence of the
noninferiority of 1.25-mg bevacizumab compared with
0.5-mg ranibizumab in the treatment of patients with ME
secondary to RVO.2Methods
Study Design and Study Population
The BRVO study was a multicenter, randomized, double-masked,
noninferiority clinical trial. This study is registered with Clinical-
Trials.gov (identiﬁer, NCT01635803) and Trialregister.nl (identi-
ﬁer, NTR3257). A total of 286 patients were included from June
2012 through February 2018. Patients were recruited at 8 clinical
centers throughout The Netherlands. The Medical Ethical Com-
mittee of the Amsterdam University Medical Centers, location
AMC, approved the BRVO study. The study adhered to the prin-
ciples of the Declaration of Helsinki. Patients were given at least 1
week to read the Patient Information Form, and each participant
provided written informed consent before randomization. Patients
with vision loss resulting from ME secondary to RVO who might
beneﬁt from anti-VEGF treatment were eligible for participation in
the study. Other inclusion criteria were age older than 18 years,
central area thickness of more than 275 mm on OCT, and a best-
corrected visual acuity (BCVA) of more than 24 and less than
79 letters on the standardized Early Treatment Diabetic Retinop-
athy Study chart. The exclusion criteria are listed in Table S1
(available at www.ophthalmologyretina.org).
Eligibility was determined during the screening visit (<14 days
before baseline) and based on visual acuity, ﬂuorescein angiog-
raphy ﬁndings, OCT ﬁndings, and slit-lamp examination results.
Diagnosis of BRVO, CRVO, or hemi-CRVO was conﬁrmed by the
Belfast Reading Centre, part of the Network of Ophthalmic Reading
Centers in the United Kingdom. At screening and after 6 months, a
more extensive examination was performed consisting of ﬂuores-
cein angiography, fundus photography, measurement of intraocular
pressure, OCT, and slit-lamp examination of both eyes. Monthly
ophthalmic examinations during follow-up consisted of BCVA and
OCT of the study eye only. In addition, blood pressure, pulse, and
weight were determined monthly (Fig S1, available at
www.ophthalmologyretina.org). Best-corrected visual acuity was
measured by certiﬁed personnel following protocol and using the
standardized Early Treatment Diabetic Retinopathy Study chart.
OCT was performed with a Heidelberg Spectralis (Heidelberg En-
gineering, Heidelberg, Germany), Topcon (Topcon, Tokyo, Japan),
or Cirrus Zeiss (Carl Zeiss Meditec, Dublin) device, depending on
availability at the participating center. For statistical analysis,
central area thickness measured by the Topcon or Cirrus Zeiss
device was converted to Heidelberg Spectralis values using the
conversion table of Giani et al.22
Interventions
Participants received the ﬁrst intravitreal injection of either 1.25 mg
bevacizumab (Avastin; Genentech, South San Francisco, CA/
Hoffman-La Roche, Basel, Switzerland) or 0.5 mg ranibizumab
(Lucentis; Genentech, South San Francisco, CA/Novartis, Inc,
Basel, Switzerland) at the baseline visit. The study drug was
administered monthly for a period of 6 months, with an interval
between injections of 307 days. Both medications were recon-
stituted and supplied by the hospital pharmacy in masked injection
syringes containing a sterile solution of 0.15 ml of 10 mg/ml
ranibizumab or 0.15 ml of 25 mg/ml bevacizumab, and the injec-
tion was given within 24 hours after preparation at a volume of
0.05 ml. The syringes were labeled with only the study identiﬁ-
cation number of the patient. Therefore, the patient, treating
physician, and evaluating investigator staff were blinded to
treatment allocation. The randomization procedure was computer
and web based using permuted blocks (minimal 2 patients,
maximal 4 patients) and stratiﬁed for center, BCVA of the study
Vader et al  Bevacizumab and Ranibizumab for RVOeye (52 letters or fewer vs. 53 letters or more), and RVO subtype
(CRVO or BRVO).
Outcomes
The primary outcome was the change in BCVA of the study eye
from baseline to 6 months, with a noninferiority margin of 4 letters.
Secondary outcome measures were the proportion of participants
with a loss or gain in BCVA of fewer than 15 letters from baseline
to 6 months (stabilizers), the proportion of participants with a loss
in BCVA of 15 letters or more from baseline to 6 months (losers),
the proportion of participants with a gain in BCVA of 15 letters or
more from baseline to 6 months (gainers), the change in central
area thickness from baseline to 6 months, the proportion of patients
who left the study prematurely, the occurrence of (severe) adverse
events during the study period, and the change in intraocular
pressure from baseline to 6 months.
Sample Size Calculation
At the start of the study, the sample size calculation for 80% power
demonstrating noninferiority required a sample size of 296 patients
(148 patients in each group), starting from a standard deviation
(SD) for the change in BCVA of 14 letters from baseline to 6
months in both groups, and assuming an improvement of 9 letters
in the ranibizumab group and bevacizumab group. Noninferiority
was demonstrated by excluding a difference of 4 letters or more
using a 1-sided t test at an a level of 0.05. The SD of 14 letters and
mean change of 9 letters were based on previous clinical trials with
ranibizumab in RVO patients, and the noninferiority margin cho-
sen was equivalent to less than half this improvement.9,10
After checking the assumed SD for the change in BCVA in the
blinded study data in February 2018, the sample size was adjusted
based on the lower observed SD of 12.1 letters. Still assuming an
improvement of 9 letters in both treatment groups, a sample size of
228 patients (114 in each group) was calculated to give 80% power
demonstrating noninferiority. For this reason, inclusion was halted
at 286 patients in March 2018.
Statistical Analysis
Intention-to-treat analysis was performed, and all randomized
patients who received the allocated treatment at least once and for
whom BCVA and OCT measurements were performed afterward
were included in the analysis. The last available BCVA score was
used as BCVA at 6 months (last observation carried forward). If
patients missed an injection during follow-up, the BCVA mea-
surement from the previous visit was used as the last available
BCVA. Noninferiority was tested using a 1-sided test, and bev-
acizumab was considered noninferior to ranibizumab if the lower
bound of the 2-sided 90% conﬁdence interval (CI) of the differ-
ence in the change in BCVA did not exceed the noninferiority
margin of 4 letters. To evaluate the inﬂuence of the last obser-
vation carried forward, a linear mixed-effects regression analysis
was performed to analyze the repeatedly measured change in
BCVA from baseline to 6 months. The proportion of stabilizers,
losers, and gainers were compared between treatment groups
using the linear-by-linear association test. The change in central
area thickness as measured by OCT from baseline to 6 months
was analyzed between treatment groups using covariance anal-
ysis. Anatomic outcomes are presented without carrying out the
last observation carried forward method, because covariance an-
alyses demonstrated similar OCT outcomes both with and without
the last observation carried forward method. The proportion of
early dropouts was compared between treatment groups using the
Pearson chi-square test. Adverse events were coded according
to the Medical Dictionary for Regulatory Activities system(MedDRA; version 20.0). The numbers and proportions of
(serious) adverse events during the study period were compared
between treatment groups using the ManneWhitney U test and
Pearson chi-square test. Patients who received at least 1 injection
were included in this analysis. A signiﬁcance level of 0.05 was
applied for all statistical tests.
Based on the stratiﬁcation criteria, a predeﬁned subgroup
analysis was performed to compare changes in visual acuity and
central area thickness between treatment arms in patients with
BRVO and CRVO or hemi-CRVO. Because hemi-CRVO is
considered to be clinically and pathogenetically closely correlated
to CRVO,23 hemi-CRVO patients were included in the CRVO
subgroup for analysis. However, because of a stratiﬁcation error,
some hemi-CRVO patients were randomized in the BRVO group.
Despite these errors, patients with BRVO, CRVO, and hemi-
CRVO were all distributed equally over both treatment arms
(Table 1). Because no imbalance of RVO types over treatment
groups occurred, noninferiority outcomes and secondary
outcomes were not affected. Regarding stratiﬁcation based on
BCVA of the study eye at baseline, the distribution of patients in
the 2 subgroups (BCVA, 52 letters or 53 letters at baseline)
was misaligned, with 200 patients and 77 patients, respectively.
Therefore, a post hoc analysis was performed on 2 subgroups
derived from the median of 63 letters at baseline in both
treatment arms (BCVA 62 letters, approximately <20/63 at
baseline; or BCVA 63 letters, approximately 20/63 at
baseline). Such an analysis based on the median was introduced
by the Diabetic Retinopathy Clinical Research Network Protocol
T study, which found signiﬁcant differences between anti-VEGF
agents in patients with lower baseline BCVA.18,19 Primary and
secondary outcomes in subgroup analyses were assessed using
the same statistical tests described above.Results
Patient Characteristics
From June 2012 through February 2018, 286 participants were
randomized to receive either bevacizumab (n ¼ 144) or ranibizu-
mab (n ¼ 142). It took almost 6 years to enroll the necessary
number of patients, because referrals from general ophthalmolo-
gists to the academic study sites decreased considerably during the
study period. Eventually, 139 patients in the bevacizumab group
and 138 patients in the ranibizumab group were available for
analysis (Fig S2, available at www.ophthalmologyretina.org). Of
all participants analyzed, 133 were diagnosed with BRVO
(48%), 97 were diagnosed with CRVO (35%), and 47 were
diagnosed with hemi-CRVO (17%). The mean visual acuity
(SD) at baseline was 60.314.8 letters in the group receiving
bevacizumab and 59.016.7 letters in the group receiving ranibi-
zumab (P ¼ 0.203). The mean central area thickness was
602.3201.2 mm in the bevacizumab group and 615.2217.3 mm
in the ranibizumab group (P ¼ 0.607). The number of current
smokers was twice as high in the bevacizumab group (14.4% vs.
7.2%), but this difference was not signiﬁcant (P ¼ 0.101). An
equal number of patients in both study arms demonstrated classical
risk factors for RVO developing, such as hypertension, hyper-
cholesterolemia, and diabetes mellitus (Table 1). The mean
duration between follow-up visits was 29.41.2 days in the bev-
acizumab group and 29.51.2 days in the ranibizumab group (P ¼
0.606). Patients in both groups received a mean of 5.90.050 in-
jections (P ¼ 0.373).3
Table 1. Baseline Characteristics of the Study Patients
Baseline Characteristics Bevacizumab (n [ 139) Ranibizumab (n [ 138)
Age (yrs), mean (SD) 68.3 (11.84) 67.4 (11.6)
Gender, no. (%)
Female 76 (54.7) 69 (50)
Male 63 (45.3) 69 (50)
Ethnicity, no. (%)
Dutch 121 (87.1) 119 (86.2)
Moroccan 1 (0.7) 3 (2.2)
Surinamese 9 (6.5) 6 (4.3)
Netherlands Antilles & Aruba 2 (1.4) 1 (0.7)
Other non-Western immigrant 4 (2.9) 7 (5.1)
Other Western immigrant 2 (1.4) 2 (1.4)
Smoking behavior, no. (%)
Smoker 20 (14.4) 10 (7.2)
Former smoker 55 (39.6) 67 (48.6)
Nonsmoker 64 (46.0) 61 (44.2)
Visual acuity of study eye (letters), mean (SD) 60.3 (14.8) 59.0 (16.7)
Central area thickness (mm), mean (SD) 602.3 (201.2) 615.2 (217.3)
Intraocular pressure (mmHg), mean (SD) 14.7 (2.8) 14.2 (3.1)
Retinal vein occlusion subtype, no. (%)
BRVO 62 (44.6) 71 (51.4)
CRVO 51 (36.7) 46 (33.3)
Hemi-CRVO 26 (18.7) 21 (15.2)
Systolic blood pressure (mmHg), mean (SD) 146.9 (19.1) 149.3 (18.3)
Diastolic blood pressure (mmHg), mean (SD) 84.0 (11.1) 85.2 (11.6)
Presence of intraretinal cysts in study eye, no. (%)
Absent 3 (2.2) 3 (2.2)
Deﬁnite 134 (96.4) 133 (96.4)
Questionable 1 (0.7) 2 (1.4)
Cannot grade 1 (0.7) 0 (0)
Presence of subretinal ﬂuid in study eye, no. (%)
Absent 44 (31.7) 47 (34.1)
Deﬁnite 77 (55.4) 73 (52.9)
Questionable 16 (11.5) 14 (10.1)
Cannot grade 2 (1.4) 4 (2.9)
Prior retinal vein occlusion of study eye, no. (%) 19 (13.7) 17 (12.3)
Prior anti-VEGF treatment of study eye, no. (%) 4 (2.9) 6 (4.3)
Prior photocoagulation treatment of study eye, no. (%) 2 (1.4) 3 (2.2)
History of hypertension, no. (%) 80 (57.6) 84 (60.9)
History of myocardial infarction, no. (%) 7 (5.0) 11 (8.0)
History of transient ischemic attack, no. (%) 4 (2.9) 6 (4.3)
History of diabetes mellitus, no. (%) 23 (16.5) 22 (15.9)
History of hypercholesterolemia, no. (%) 38 (27.3) 28 (20.3)
History of thrombosis, no. (%) 3 (2.2) 1 (0.7)
History of cerebrovascular accident, no. (%) 4 (2.9) 4 (2.9)
Body mass index (kg/m2), mean (SD) 26.7 (4.8) 27.1 (4.0)
BRVO ¼ branch retinal vein occlusion; CRVO ¼ central retinal vein occlusion; SD ¼ standard deviation; VEGF ¼ vascular endothelial growth factor.
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Visual acuity improved to identical levels in both treatment groups
after 6 months, with a mean gain of 15.313.0 letters in the
bevacizumab group and 15.513.3 letters in the ranibizumab
group (Table 2; Fig 1A). The lower bound of the 2-sided 90% CI
for the change in BCVA from baseline to 6 months was e1.724
letters. This is within the chosen noninferiority margin of 4 letters,
demonstrating that monthly bevacizumab is noninferior to monthly
ranibizumab in the treatment of ME resulting from RVO (Fig 2).
To evaluate the inﬂuence of carrying forward the last available
BCVA scores to month 6 in patients without a BCVA score at 6
months (n ¼ 19), a linear mixed-effects regression analysis was
performed. This gave us a lower bound of the 2-sided 90% CI of4e2.819 letters, conﬁrming noninferiority, because it also excludes
the noninferiority margin of 4 letters.
Secondary Outcomes
The proportion of stabilizers (loss or gain of <15 letters from
baseline), losers (loss of 15 letters from baseline), and gainers
(gain of 15 letters from baseline) did not differ between treatment
groups (P ¼ 0.684; Table 2). The decrease in central area thickness
from baseline to 6 months was also equivalent between groups,
because bevacizumab resulted in a decrease of 287.0231.3 mm
and ranibizumab resulted in a decrease of 300.8224.8 mm
(P ¼ 0.694; Table 2; Fig 3A). The presence of subretinal ﬂuid
and intraretinal cysts did not differ between treatment arms at
Table 2. Primary and Secondary Outcomes after 6 Months
Outcomes
Bevacizumab
(n [ 139)
Ranibizumab
(n [ 138)
Lower Bound of the 90%
Conﬁdence Interval* P Value
Primary
Change in visual acuity of
study eye (letters), mean (SD)
Month 1 10.1 (10.5) 9.8 (10.8) e1.048
Month 2 12.0 (12.4) 12.9 (12.3) e2.428
Month 3 13.2 (12.3) 14.1 (12.5) e2.494
Month 4 14.8 (12.2) 15.0 (13.1) e1.727
Month 5 14.6 (13.2) 16.1 (13.4) e2.989
Month 6 15.3 (13.0) 15.5 (13.3) e1.724
Mean visual acuity at 6
months (letters), mean (SD)
75.6 (12.13) 74.5 (14.7)
Secondary
Proportion of, no (%) 0.684
Stabilizers (loss or gain <15 letters from baseline) 68 (48.9) 73 (52.9)
Losers (loss 15 letters from baseline) 2 (1.4) 1 (0.7)
gainers (gain 15 letters from baseline) 69 (49.6) 64 (46.4)
Change in central area thickness (mm), mean (SD)
Month 1 e242.5 (201.5) e243.1 (205.4)
Month 2 e262.0 (215.9) e273.6 (216.9)
Month 3 e281.7 (221.1) e271.9 (220.5)
Month 4 e279.2 (222.1) e289.4 (230.2)
Month 5 e290.9 (220.4) e304.7 (223.1)
Month 6 e287.0 (231.3) e300.8 (224.8) 0.694
Mean central area thickness at
6 months (mm), mean (SD)
314.6 (115.0) 310.0 (89.5)
Intraretinal cysts on OCT at 6 months, no (%) 0.015
Absent 65 (48.5) 82 (55.8)
Deﬁnite 57 (42.5) 39 (31.5)
Questionable 9 (6.7) 2 (1.6)
Cannot grade 3 (2.2) 1 (0.8)
Subretinal ﬂuid on OCT at 6 months, no (%) 0.642
Absent 118 (88.1) 113 (91.1)
Deﬁnite 7 (5.2) 7 (5.6)
Questionable 4 (3.0) 2 (1.6)
Cannot grade 5 (3.7) 2 (1.6)
Proportion of dropouts, no (%) 4 (2.9) 8 (5.8) 0.233
Change in systolic blood pressure
from baseline to 6 mos (mmHg), mean (SD)
e4.7 (21.7) e3.4 (19.4) 0.204
Systolic blood pressure at 6 mos (mmHg), mean (SD) 142.3 (19.1) 146.0 (18.0)
Change in diastolic blood pressure from
baseline to 6 mos (mmHg), mean (SD)
e1.8 (10.9) e1.9 (11.0) 0.768
Diastolic blood pressure at
6 mos (mmHg), mean (SD)
82.5 (9.6) 83.2 (11.7)
Intraocular pressure (mmHg), mean (SD) 15.0 (3.2) 15.4 (3.1)
Change in intraocular pressure from
baseline to 6 mos (mmHg), mean (SD)
0.3 (3.1) 1.2 (3.6) 0.083
SD ¼ standard deviation.
Bolding indicates signiﬁcant P value.
*The lower bound of the 2-sided 90% conﬁdence interval of the difference in the change in visual acuity is noted as an outcome for noninferiority.
Bevacizumab is considered noninferior to ranibizumab if the noninferiority margin of 4 letters can be excluded.
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proportion of patients with intraretinal cysts was higher in the
bevacizumab group (42.5% vs. 31.5% in the ranibizumab group;
P ¼ 0.015), whereas subretinal ﬂuid was absent in most patients
(88.1% and 91.1%, respectively; P ¼ 0.642). Four patients (2.9%)
in the bevacizumab group and 8 patients (5.8%; P ¼ 0.233) in the
ranibizumab group did not complete the 6-month study protocol.
Reasons for early termination included a severe adverse event not
related to study medication, adverse event not related to study
medication, progression of ischemia for which laser treatment wasindicated, and death (Table 2). After 6 months, intraocular pressure
exhibited a trend of a minimal increase compared with baseline in
both the bevacizumab group (0.33.1 mmHg) and ranibizumab
group (1.23.6 mmHg; P ¼ 0.083; Table 2).
Subgroup Analysis: Baseline Best-Corrected
Visual Acuity
Post hoc analysis was performed based on the median visual acuity
score at baseline, that is, in the subgroup of patients with BCVA of5
Figure 1. Graphs showing mean change in visual acuity from baseline to 6 months: (A) entire cohort, (B) patients with an initial visual acuity of 62 letters
or fewer, and (C) patients with an initial visual acuity of 63 letters or more. CI ¼ conﬁdence interval.
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n ¼ 143) versus those with a baseline BCVA of 62 letters or fewer
(Snellen equivalent, approximately <20/63; n ¼ 134; Table 3; Fig
1B, C). Patients who started with initially higher baseline vision
(63 letters) gained a mean of 8.39.5 letters in the
bevacizumab group and 10.57.0 letters in the ranibizumabFigure 2. Graph showing the 2-sided 90% conﬁdence intervals, with a
noninferiority margin of 4 letters. Bevacizumab could be considered non-
inferior in both the entire cohort and in patients with a baseline visual
acuity of 62 letters or fewer. The outcomes for the group with an initially
higher baseline visual acuity are inconclusive. BCVA ¼ best corrected
visual acuity.
6group; the lower limit of the 2-sided 90% CI was e4.359 letters,
exceeding the noninferiority margin of 4 letters (Fig 3). However,
these subgroups were not powered to reject noninferiority. Patients
in the subgroup with a baseline BCVA of 62 letters or fewer
showed an improvement of 22.612.1 letters with bevacizumab
and 21.016.2 letters with ranibizumab (lower bound of the
2-sided 90% CI, e0.703 letter). Central area thickness decreased
182.2184.0 mm in patients with a higher initial BCVA who
received bevacizumab and 208.7161.1 mm in those receiving
ranibizumab (P ¼ 0.052; Fig 2B, C). Comparing central area
thickness between bevacizumab and ranibizumab in patients with
an initially lower BCVA showed a decrease of 396.5226.0 mm
and 401.5241.9 mm, respectively (P ¼ 0.093). When we
compared the differences in OCT outcomes between the
bevacizumab and ranibizumab groups with low and high baseline
visual acuity, we found a signiﬁcant difference between the 2
subgroups, because a larger difference was seen in the decrease
in central area thickness between bevacizumab and ranibizumab
in the patient group with higher initial visual acuity (P ¼ 0.012;
Table 3).
Subgroup Analyses: Retinal Vein Occlusion Type
In patients with BRVO (n ¼ 133), the mean gain in BCVA from
baseline to 6 months was 14.211.2 letters in the bevacizumab
group and 14.010.2 letters in the ranibizumab group (lower
bound of the 2-sided 90% CI, e2.950 letters). The CRVO sub-
group (n ¼ 144) included patients diagnosed with CRVO (n ¼ 97)
Figure 3. Graphs showing mean change in central area thickness from baseline to 6 months: (A) entire cohort, (B) patients with an initial visual acuity of
62 letters or fewer, and (C) patients with an initial visual acuity of 63 letters or more.
Vader et al  Bevacizumab and Ranibizumab for RVOand hemi-CRVO (n ¼ 47). Patients in this group gained 16.114.3
letters with bevacizumab and 17.115.8 letters with ranibizumab
(lower bound of the 2-sided 90% CI, e1.741 letters). The
noninferiority of bevacizumab to ranibizumab could be demon-
strated in both RVO subgroups (Table S2, available at
www.ophthalmologyretina.org). The central area thickness
decreased in all RVO types from baseline to 6 months, at equal
levels in the bevacizumab and ranibizumab groups. The mean
change in central area thickness was 232.0199.9 mm in BRVO
patients receiving bevacizumab and 214.3176.5 mm in BRVO
patients receiving ranibizumab (P ¼ 0.513). Among CRVO and
hemi-CRVO patients, the bevacizumab group exhibited a
decrease in central area thickness of 332.5246.5 mm and the
ranibizumab group showed a decrease of 398.3234.4 mm (P ¼
0.976; Table S2).
Adverse Events
All patients who received at least 1 injection were included in the
safety analysis (Table 4). No difference was found in the number of
patients with adverse events between the bevacizumab and
ranibizumab groups (P ¼ 0.505). Severe adverse events were
distributed equally across both treatment arms (P ¼ 0.509).
Three arteriothrombotic events occurred in the bevacizumab
group and 1 occurred in the ranibizumab group, but this
difference was not signiﬁcant. All arteriothrombotic events were
classiﬁed by the local investigator as being unrelated to the study
medication. The frequency of adverse events in the MedDRAsystem organ classes was signiﬁcantly different between
bevacizumab and ranibizumab only for General Disorders and
Administration Site Conditions (P ¼ 0.030; Table S3, available
at www.ophthalmologyretina.org). Adverse events appointed to
this MedDRA class included reports of fever, a sore throat, or
the ﬂu in between study visits and pain after injection, burning
sensations after the injection, or a hyposphagma after injection.
Again, all adverse events in this class were graded as being
unrelated to the study medication.Discussion
This study showed that, based on changes in BCVA from
baseline to 6 months, monthly administration of 1.25 mg
bevacizumab is noninferior to monthly administration of 0.5
mg ranibizumab in the treatment of patients with macular
edema resulting from RVO. Furthermore, no signiﬁcant
differences were seen in anatomic or safety outcomes. In
both treatment groups, the mean BCVA improved sub-
stantially from baseline to 6 months, which is consistent
with the visual acuity outcomes found in other studies, such
as the BRAVO study, which compared 0.5-mg ranibizumab
to sham injections and observed a mean gain of 18.3 letters
after 6 months in patients with BRVO.9 Similarly, the
Ranibizumab for the Treatment of Macular Edema after
Central Retinal Vein OcclUsIon Study: Evaluation of
Efﬁcacy and Safety (CRUISE) study demonstrated an7
Table 3. Primary and Secondary Outcomes Based on Visual Acuity at Baseline
Outcomes
Visual Acuity at Baseline ‡63 Letters (n [ 143) Visual Acuity at Baseline £62 Letters (n [ 134)
P Valuey
Bevacizumab
(n ¼ 71)
Ranibizumab
(n ¼ 72)
Lower Bound 90%
Conﬁdence Interval* Bevacizumab (n ¼ 68) Ranibizumab (n ¼ 66)
Lower Bound 90%
Conﬁdence Interval*
Primary outcomes
Visual acuity at baseline 71.7 (5.2) 71.5 (5.08) 48.32 (11.82) 45.26 (13.96)
Change in visual acuity of study eye
(letters)
Month 1 4.5 (7.2) 6.9 (7.0) e4.253 16.0 (10.2) 12.9 (13.2) 0.864
Month 2 6.0 (9.1) 8.5 (7.9) e4.705 18.3 (12.3) 17.6 (14.4) e1.891
Month 3 6.7 (8.0) 9.4 (7.7) e4.732 19.9 (12.6) 19.3 (14.6) e1.925
Month 4 7.9 (8.3) 10.3 (7.0) e4.452 21.9 (11.5) 20.0 (16.1) e0.581
Month 5 7.4 (9.6) 11.4 (7.4) e6.296 22.2 (12.1) 21.1 (16.5) e1.202
Month 6 8.3 (9.5) 10.5 (7.0) e4.359 22.6 (12.1) 21.0 (16.2) e0.703
Visual acuity at 6 months 80.0 (9.4) 82.0 (7.3) 70.9 (13.0) 66.2 (16.3)
Secondary outcomes P Value P Value
Central area thickness at baseline (mm) 517.4 (156.8) 509.3 (158.8) 690.8 (205.3) 730.8 (214.4)
Change in central area thickness (mm)
Month 1 e169.4 (164.1) e185.1 (155.0) e319.0 (209.5) e306.4 (234.2)
Month 2 e176.4 (169.9) e195.3 (160.1) e352.9 (223.4) e363.1 (238.8)
Month 3 e183.3 (168.4) e199.2 (169.4) e383.1 (224.2) e354.0 (243.1)
Month 4 e181.7 (168.5) e202.0 (153.0) e379.6 (226.8) e384.9 (261.7)
Month 5 e190.9 (164.5) e215.3 (160.3) e395.6 (223.8) e402.9 (241.5)
Month 6 e182.2 (184.0) e208.7 (161.1) 0.052 e396.5 (226.0) e401.5 (241.9) 0.093 0.012
Central area thickness at 6 mos (mm) 332.8 (139.9) 296.8 (56.0) 295.6 (78.0) 324.4 (114.3)
Data are mean (standard deviation) unless otherwise indicated.
*The lower bound of the 2-sided 90% conﬁdence interval of the difference in the change in visual acuity is noted as an outcome for noninferiority. Bevacizumab is considered noninferior to ranibizumab if
the noninferiority margin of 4 letters can be excluded.
yP value for visual acuity at baseline  treatment group interaction on central area thickness outcome.
O
phthalm
ology
R
etina
V
olum
e
-
,
N
um
ber
-
,
M
onth
2020
8
Table 4. Adverse Events and Severe Adverse Events during the
Study Period
Event*
Bevacizumab
(n [ 140)
Ranibizumab
(n [ 140) P Value
Adverse events
Any adverse event 97 (69.3) 92 (67.5) 0.505
Elevated intraocular pressure 2 (1.4) 2 (1.4) 1.000
Uveitis 1 (0.7) 1 (0.7) 1.000
Venous thrombotic event 1 (0.7) 0 0.316
Hypertension 25 (17.9) 23 (16.4) 0.751
1 Adverse event 60 (42.9) 55 (39.3) 0.544
Severe adverse events
Any severe adverse event 10 (7.1) 13 (9.2) 0.509
Death from any cause 0 2 (1.4) 0.156
Arteriothrombotic event
Nonfatal myocardial
infarction
2 (1.4 ) 0 0.156
Nonfatal stroke 1 (0.7) 0 0.316
Angina pectoris 0 1 (0.7) 0.316
Transient ischemic attack 2 (1.4) 1 (0.7) 0.562
1 Severe adverse event 2 (1.4) 3 (2.1) 0.652
Acute glaucoma 1 (0.7) 0 0.316
Macular hole 0 1 (0.7) 0.316
Severe anterior uveitis 0 1 (0.7) 0.316
Data are no. (%).
*Multiple events in the same study patient were counted only once.
Vader et al  Bevacizumab and Ranibizumab for RVOimprovement of 14.9 letters in the BCVA of CRVO patients
treated with 0.5-mg ranibizumab after 6 months.10 For
bevacizumab, Epstein et al6 demonstrated an improvement
of 14.1 letters after 6 months in CRVO patients. Focusing
on visual acuity outcomes in RVO subgroups, our study
demonstrated greater improvement in visual acuity in
CRVO and hemi-CRVO patients than BRVO patients. In
contrast, previous studies found greater improvement of
visual acuity in BRVO patients than other studies that
included patients with CRVO.6,9,10
In our study, the percentage of patients who gained 15
letters or more after 6 months was 49.6% in the bevacizumab
group and 46.4% in the ranibizumab group, which is slightly
lower than the proportions reported in the BRAnch Retinal
Vein Occlusion: Evaluation of Efﬁcacy and Safety (BRAVO)
study (61.1%) and the study by Epstein et al6 (60%) but
comparable with the CRUISE study (47.7%). Central area
thickness outcomes on OCT were of a similar magnitude in
our study as the studies listed above.1,9,10
The SCORE2 trial compared bevacizumab with aﬂi-
bercept in patients with CRVO and hemi-CRVO, demon-
strating a mean increase in visual acuity of 18.6 letters and
18.9 letters, respectively.1 The proportion of gainers
(improvement of 15 letters after 6 months) was 61.3%
in the bevacizumab arm and 65.1% in the aﬂibercept arm.
The SCORE2 trial included patients with lower baseline
visual acuity (BCVA of 19e73 letters) and higher central
subﬁeld thickness limit (300 mm) than our trial, which
could explain the slightly better visual outcome after 6
months.
As in the entire cohort, noninferiority of bevacizumab to
ranibizumab could be demonstrated in the subgroup ofpatients with an initially lower BCVA (62 letters), but
noninferiority in the subgroup with an initially higher
BCVA (63 letters) was inconclusive because of the low
sample size and because the CI of the difference between
study arms in visual acuity from baseline to 6 months
included both 0 and the noninferiority margin (Fig 3).24
Interestingly, the subgroup with a higher baseline VA
showed an unexpectedly better outcome for ranibizumab
in visual acuity outcome than bevacizumab, with a mean
difference of 2.2 letters between treatment arms. This is a
smaller difference than the 4-letter noninferiority margin
used in our study, but because of the ceiling effect that is
associated with a low maximal gain in BCVA and OCT in
this subgroup, even this small difference may point at a true
and clinically meaningful advantage of ranibizumab in pa-
tients with a higher baseline BCVA. Our ﬁndings seem to be
in contrast with the SCORE2 study, which did not ﬁnd
differences in treatment effect of aﬂibercept and bev-
acizumab between subgroups with a worse (20/50e20/320)
or better (20/32e20/40) baseline BCVA. However, because
they used the same cutoff value as the Diabetic Retinopathy
Clinical Research Network Protocol T study to determine
subgroups based on baseline BCVA, 2 unbalanced cohorts
were compared with only 38 of 362 patients assigned to the
subgroup with a higher baseline BCVA.1 In diabetic
macular edema, the protocol T study compared the
efﬁcacy of 1.25-mg bevacizumab, 0.3-mg ranibizumab,
and 2.0-mg aﬂibercept. In a similar analysis, subgroups of
patients with an initially lower or higher BCVA, based on
the median visual acuity, were compared. Patients with an
initial worse BCVA (<69 letters [20/50]) demonstrated
signiﬁcantly better visual acuity and OCT outcomes with
aﬂibercept compared with both bevacizumab and ranibizu-
mab after 1 year of treatment. This difference, which was
exactly the reverse of our ﬁndings in RVO patients, was
maintained for 2 years in the comparison between bev-
acizumab and aﬂibercept only.18,19 We do not have a direct
explanation of this difference between RVO and diabetic
ME patients in response to different anti-VEGF agents.
One might hypothesize that better outcomes with ranibizu-
mab in patients with a higher baseline visual acuity in RVO
may be explained by the speciﬁc pathogenesis of RVOs, in
which hydrostatic capillary pressure and retinal ischemia
may play different roles in the development of macular
edema and irreversible and functional retinal damage, than
in diabetic ME, in which longstanding capillary loss and
chronic parainﬂammation may be more important.25,26
Another signiﬁcant difference between treatment groups
was the number of participants who still demonstrated intra-
retinal cysts on OCT after 6 months. Notably, this was graded
by the local investigators, without conﬁrmation by an external
reading center. This observation was consistent with the
ﬁndings of the Comparison of Age-Related Macular Degen-
eration Treatments Trials and the Bevacizumab to Ranibizu-
mab in exudative Age-related Macular Degeneration
(BRAMD) trial in exudative age-relatedmacular degeneration,
in which ﬂuid was seen on OCT in signiﬁcantly more patients
in the bevacizumab arm than the ranibizumab arm after 1
year.11,12 Similarly, in the SCORE2 trial, the number of study
eyes with no subretinal ﬂuid, no intraretinal ﬂuid, and no9
Ophthalmology Retina Volume -, Number -, Month 2020cystoid spaces in CRVO patients after 6 months was
signiﬁcantly higher in the aﬂibercept group than the
bevacizumab group.1 Although these 3 studies demonstrated
differences in visible ﬂuid on OCT after anti-VEGF treat-
ment, as in our present study, no corresponding differences in
visual outcomewere noted, suggesting that these differences in
visible ﬂuid do not inﬂuence visual acuity outcome.
Overall, the rates of adverse events and severe adverse
events in our study were similar in both treatment groups,
which is consistent with safety outcomes in other compar-
ative trials of anti-VEGF agents.1,11,16,18,19,27 Signiﬁcantly
more patients treated with bevacizumab experienced an
adverse event in the MedDRA system organ class General
Disorders and Administration Site Conditions. However, it
is plausible that this difference is the result of chance,
because the administration protocol was the same for both
drugs. In addition, we do not have a reason to believe that
either one of the anti-VEGF treatments inﬂuences the risk
of general disorders such as fever or a sore throat, nor the
risk of administration site conditions such as a painful eye or
burning sensations after injection.
Intravenous treatment of cancer patientswith bevacizumab
is associated with an increased risk of hypertension, impaired
wound healing, hemorrhages, venous thrombosis, and arte-
riothrombotic events.28,29 We did not ﬁnd signiﬁcant
differences between bevacizumab and ranibizumab in the
occurrence of these adverse events, but our sample size was
not calculated to give conclusive evidence regarding safety
differences between bevacizumab and ranibizumab.
Our study has additional limitations. First, the study lacked a
comparison with the third commonly used anti-VEGF agent,
aﬂibercept. At the time this study started, aﬂibercept was not yet
available inTheNetherlands. Second, the follow-upwas limited
to 6months, whenmost improvement, if any, occurs. However,
it is plausible that our outcomes have predictive value for more
long-term outcomes. Third, our study included patients with a
central area thickness of 275 mm or more, whereas most
comparative anti-VEGF trials use a cutoff value of 300 mm, and
this could potentially alter primary and secondary out-
comes.1,18,19 Nevertheless, only 4 patients demonstrated a
central area thickness of less than 300 mm at baseline, and in
general, our BCVA and OCT outcomes were comparable
with those of previous studies. Fourth, secondary and post
hoc analyses based on RVO subtype and baseline visual
acuity were performed but should be regarded as exploratory
because of insufﬁcient power to exclude noninferiority or
detect small but potentially clinically relevant differences
between treatment arms in these subgroups.
Three different spectral-domain OCT devices were used
for central area examination. Each device has its own for-
mula to convert pixel volume to micrometers, which makes
OCT measurements from different devices incomparable.30
Therefore, all OCT measurements were converted to
Heidelberg Spectralis outcomes using the conversion table
by Giani et al.22 However, the software used by the
devices in this study differed from the software on which
Giani et al based their conversion table. However,
minimal changes were expected from software updates.
In conclusion, based on visual acuity outcomes after 6
months treatment, our results demonstrate the noninferiority10of 1.25 mg bevacizumab to 0.5 mg ranibizumab in the treat-
ment of patients with macular edema resulting from RVO.
Visual acuity gain, anatomic outcomes, and safety were
remarkably equivalent at 6 months in both treatment arms,
independent of RVO subtype. In our study, patients were
treated monthly for 6 months, which is more frequent than
most common regimens in daily practice. In addition, we
cannot predict long-term outcomes based on our ﬁndings.
However, because we conducted a representative randomized
clinical trial with an extensive scope of eligibility criteria, and
because patients were included in both academic and
nonacademic centers throughout The Netherlands, our results
are likely generalizable to a broad group of patients and
indicate that bevacizumab may be an effective alternative to
ranibizumab in the treatment of RVO.
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